Chemomab Total Cash From Operating Activities from 2010 to 2024
| CMMB Stock | USD 0.73 0.03 4.29% |
Total Cash From Operating Activities | First Reported 2010-12-31 | Previous Quarter -23.6 M | Current Value -22.4 M | Quarterly Volatility 5.8 M |
Check Chemomab Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chemomab main balance sheet or income statement drivers, such as Selling General Administrative of 6.7 K, Other Operating Expenses of 20.4 M or Research Development of 12.3 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.33. Chemomab financial statements analysis is a perfect complement when working with Chemomab Therapeutics Valuation or Volatility modules.
Chemomab | Total Cash From Operating Activities |
Latest Chemomab Therapeutics' Total Cash From Operating Activities Growth Pattern
Below is the plot of the Total Cash From Operating Activities of Chemomab Therapeutics Ltd over the last few years. It is Chemomab Therapeutics' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chemomab Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Cash From Operating Activities | 10 Years Trend |
|
Total Cash From Operating Activities |
| Timeline |
Chemomab Total Cash From Operating Activities Regression Statistics
| Arithmetic Mean | (11,952,384) | |
| Coefficient Of Variation | (48.51) | |
| Mean Deviation | 4,715,051 | |
| Median | (8,800,495) | |
| Standard Deviation | 5,798,676 | |
| Sample Variance | 33.6T | |
| Range | 18.3M | |
| R-Value | (0.72) | |
| Mean Square Error | 17.6T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (928,567) | |
| Total Sum of Squares | 470.7T |
Chemomab Total Cash From Operating Activities History
About Chemomab Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Chemomab Therapeutics income statement, its balance sheet, and the statement of cash flows. Chemomab Therapeutics investors use historical funamental indicators, such as Chemomab Therapeutics's Total Cash From Operating Activities, to determine how well the company is positioned to perform in the future. Although Chemomab Therapeutics investors may use each financial statement separately, they are all related. The changes in Chemomab Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chemomab Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Chemomab Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Chemomab Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Cash From Operating Activities | -23.6 M | -22.4 M |
Pair Trading with Chemomab Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemomab Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemomab Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Chemomab Stock
| 0.67 | VKTX | Viking Therapeutics | PairCorr |
Moving against Chemomab Stock
| 0.77 | OVID | Ovid Therapeutics Financial Report 3rd of May 2024 | PairCorr |
| 0.56 | ORGO | Organogenesis Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.55 | GNFT | Genfit | PairCorr |
| 0.5 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to Chemomab Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chemomab Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chemomab Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chemomab Therapeutics Ltd to buy it.
The correlation of Chemomab Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chemomab Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chemomab Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chemomab Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Chemomab Therapeutics Correlation against competitors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.